Evidence-based guideline update: Plasmapheresis in neurologic disorders
Top Cited Papers
- 18 January 2011
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology
- Vol. 76 (3), 294-300
- https://doi.org/10.1212/wnl.0b013e318207b1f6
Abstract
Objective: To reassess the role of plasmapheresis in the treatment of neurologic disorders. Methods: We evaluated the available evidence based on a structured literature review for relevant articles from 1995 through September 2009. In addition, due to revision of the definitions of classification of evidence since the publication of the previous American Academy of Neurology assessment in 1996, the evidence cited in that manuscript was reviewed and reclassified. Results and Recommendations: Plasmapheresis is established as effective and should be offered in severe acute inflammatory demyelinating polyneuropathy (AIDP)/Guillain-Barré syndrome (GBS) and in the short-term management of chronic inflammatory demyelinating polyneuropathy (Class I studies, Level A). Plasmapheresis is established as ineffective and should not be offered for chronic or secondary progressive multiple sclerosis (MS) (Class I studies, Level A). Plasmapheresis is probably effective and should be considered for mild AIDP/GBS, as second-line treatment of steroid-resistant exacerbations in relapsing forms of MS, and for neuropathy associated with immunoglobulin A or immunoglobulin G gammopathy, based on at least one Class I or 2 Class II studies (Level B). Plasmapheresis is probably not effective and should not be considered for neuropathy associated with immunoglobulin M gammopathy, based on one Class I study (Level B). Plasmapheresis is possibly effective and may be considered for acute fulminant demyelinating CNS disease (Level C). There is insufficient evidence to support or refute the use of plasmapheresis for myasthenia gravis, pediatric autoimmune neuropsychiatric disorders associated with streptococcus infection, and Sydenham chorea (Class III evidence, Level U).This publication has 30 references indexed in Scilit:
- Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte functionNeurology, 2009
- Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathyAnnals of Neurology, 2001
- Appropriate number of plasma exchanges in Guillain‐Barré syndromeAnnals of Neurology, 1997
- Comparative effects of plasma exchange and pyridostigmine on respiratory muscle strength and breathing pattern in patients with myasthenia gravis.Thorax, 1995
- Plasma exchange and chlorambucil in polyneuropathy associated with monoclonal IgM gammopathy. IgM-associated Polyneuropathy Study Group.Journal of Neurology, Neurosurgery & Psychiatry, 1995
- A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathyAnnals of Neurology, 1994
- Plasma Exchange in Polyneuropathy Associated with Monoclonal Gammopathy of Undetermined SignificanceThe New England Journal of Medicine, 1991
- The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosisThe Lancet, 1991
- Efficiency of plasma exchange in Guillain‐Barré syndrome: Role of replacement fluidsAnnals of Neurology, 1987
- Plasma Exchange in Chronic Inflammatory Demyelinating PolyradiculoneuropathyThe New England Journal of Medicine, 1986